CAPTRUST Financial Advisors
PRVB

CAPTRUST Financial Advisors’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

CAPTRUST Financial Advisors’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,394
Closed -$10K – 5243
2022
Q1 		$10K Buy
1,394
+17
+1% +$102 ﹤0.01% 3831
2021
Q4 		$8K Buy
1,377
+1,103
+403% +$7K ﹤0.01% 3869
2021
Q3 		$2K Sell
274
-552
-67% -$3.55K ﹤0.01% 4324
2021
Q2 		$7K Buy
826
+774
+1,488% +$6.25K ﹤0.01% 3733
2021
Q1 		$1K Buy
+52
New +$732 ﹤0.01% 4276

Other funds holding PRVB

SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

CAPTRUST Financial Advisors's PRVB Position: Q2 2022 in Review

CAPTRUST Financial Advisors sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2022, closing a stake of 1,394 shares — an estimated $10K sold.

CAPTRUST Financial Advisors first reported a position in PRVB in Q1 2021 and held it in 5 quarters. The position peaked at $10K in Q1 2022. 115 funds tracked by Wall St. Rank hold PRVB as of Q2 2022.

  • CAPTRUST Financial Advisors reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 1,394 Provention Bio, Inc. Common Stock shares in Q2 2022, an estimated $10K.
  • CAPTRUST Financial Advisors first reported a position in Provention Bio, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
  • CAPTRUST Financial Advisors's Provention Bio, Inc. Common Stock position peaked at $10K in Q1 2022.
  • 115 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2022, filed 16 Aug 2022.